Psoriatic arthritis

First, a quick recap of how we got here. Guselkumab, an IL-23p19-subunit inhibitor, was approved for moderate to severe plaque psoriasis in July 2017. With the success of DISCOVER 1 (D1) and…

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a…

The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis. I’…

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and…

Growing awareness of spondyloarthropathies over the last two decades has inevitably led to a better understanding of the pathophysiology of spondyloarthritis (SpA), and subsequently increased…

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to…

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to…

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the…